As of 2024-12-13, the Intrinsic Value of Reneo Pharmaceuticals Inc (RPHM) is
-2.35 USD. This RPHM valuation is based on the model Peter Lynch Fair Value.
With the current market price of 1.82 USD, the upside of Reneo Pharmaceuticals Inc is
-229.31%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
-2.35 USD
Intrinsic Value
RPHM Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| Fair Value |
-2.35 - -2.35 |
-2.35 |
-229.31% |
| P/E |
(9.07) - (9.23) |
(8.73) |
-579.7% |
| DDM - Stable |
(4.04) - (13.70) |
(8.87) |
-587.5% |
| DDM - Multi |
(5.07) - (13.58) |
(7.41) |
-507.0% |
RPHM Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
218.63 |
| Beta |
-0.91 |
| Outstanding shares (mil) |
120.13 |
| Enterprise Value (mil) |
182.66 |
| Market risk premium |
4.60% |
| Cost of Equity |
9.62% |
| Cost of Debt |
5.00% |
| WACC |
6.64% |